- The trend backdrop is active with a 23-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is constructive, supporting the smart-money activity read.
HIGH
GER
Week ended 07 Aug 2026
Weekly Investor Report
Cantourage Group SE · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
5.58 EUR
-2.4%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 6.7% above the Trend Line and sits at 71.8% of its 52-week range. The latest completed week returned -2.4%, after a -5.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
53
out of 100
Latest Close
5.58 EUR
7 Aug 2026
1W Return
-2.4%
latest completed week
4W Return
-5.4%
short-term follow-through
12W Return
-6.1%
quarterly tape
Trend Breadth
44.2%
23 of 52 weeks active
Volume Ratio
1.3x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-2.4%
Latest completed week; four-week move -5.4%.
Indicator stack
69/0
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
1 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 6.7% above the Trend Line and sits at 71.8% of its 52-week range. The latest completed week returned -2.4%, after a -5.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7412-week average 0.93
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.74Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -5.4% over four weeks, -6.1% over 12 weeks, and 35.4% over one year. The current trend has remained active for 23 consecutive weeks.
Performance by holding period
Active trend streak23 weeks
Active weeks in one year23
Trend breadth44.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.93Latest activity-pressure read.
Pressure change-2515.4%Four-week change in activity pressure.
Leadership16.33Latest relative-leadership reading.
RS change-48.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2023
Field coverage 70%
Model confidence 21%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength63/100Blend of value, momentum, and quality. Underlying universe rank 38; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality53/100Profitability and accounting quality. Underlying universe rank 48; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 2.8x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 31.5% Gross profit retained from each unit of revenue.
- Operating margin
- -18.4% Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -8.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 4.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 1 relevant articles.
0 positive · 1 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-18.7%Distance below the 52-week high.
13-week volatility4.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2611 weeks finished lower.
Best week+15.4%Week of 6 Mar.
Worst week-9.5%Week of 17 Jul.
Latest week-2.4%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains7
Flat weeks1
Modest losses6
Sharp losses5
Recent vol4.3%13-week weekly-return volatility.
Base vol7.3%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew6.3% / -4.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank61 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - Specialty & Generic
4-week rank8 / 10
Group average-3.6%
Trend breadth30.0%
Trend30.0%active weekly trend signals
MD40.0%positive activity pressure
RS30.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape56/100
Trend, activity pressure, participation, and risk combine to a 56/100 tape read.
Indicator analysis80/100Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 12/12.
Activity pressure 0.74; No reversal markers Factors56/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 47; Small Cap Core rank 58 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 1 relevant articles.
Cantourage UK Partners with Portocanna to Improve Affordable Medical Cannabis Access in the UK Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 5.58 EUR | -2.4% | 5.23 EUR | 5.69 EUR | -0.93 | 16.33 | 34.1K | On |
| 31 Jul 2026 | 5.72 EUR | 4.4% | 5.16 EUR | 5.73 EUR | -0.76 | 23.00 | 6.1K | On |
| 24 Jul 2026 | 5.48 EUR | 2.6% | 5.08 EUR | 5.76 EUR | -0.47 | 21.02 | 22.9K | On |
| 17 Jul 2026 | 5.34 EUR | -9.5% | 5.01 EUR | 5.80 EUR | -0.19 | 19.76 | 51.0K | On |
| 10 Jul 2026 | 5.90 EUR | -4.8% | 4.94 EUR | 5.83 EUR | 0.04 | 31.55 | 23.8K | On |
| 3 Jul 2026 | 6.20 EUR | 0.6% | 4.85 EUR | 5.86 EUR | 0.25 | 34.91 | 57 | On |
| 26 Jun 2026 | 6.16 EUR | 0.0% | 4.74 EUR | 5.89 EUR | 0.50 | 40.43 | 19.0K | On |
| 19 Jun 2026 | 6.16 EUR | -1.0% | 4.64 EUR | 5.92 EUR | 0.85 | 39.12 | 4.8K | On |
| 12 Jun 2026 | 6.22 EUR | -1.9% | 4.52 EUR | 5.96 EUR | 1.08 | 42.44 | 3.6K | On |
| 5 Jun 2026 | 6.34 EUR | -3.1% | 4.41 EUR | 5.99 EUR | 1.24 | 44.06 | 19.8K | On |
| 29 May 2026 | 6.54 EUR | 7.9% | 4.30 EUR | 6.02 EUR | 1.31 | 46.54 | 73.1K | On |
| 22 May 2026 | 6.06 EUR | 2.0% | 4.18 EUR | 6.04 EUR | 1.27 | 36.91 | 16.1K | On |
| 15 May 2026 | 5.94 EUR | -4.2% | 4.08 EUR | 6.07 EUR | 1.36 | 39.41 | 58.5K | On |
| 8 May 2026 | 6.20 EUR | 7.6% | 4.00 EUR | 6.09 EUR | 1.32 | 43.57 | 49.7K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.